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Lyme Disease Patient Care: An Exploration of the Opportunity for Quality Improvement and 








• Lyme disease (LD) is the most commonly 
reported vector borne illness in the US3
• The bacteria responsible for LD, Borrelia
burgdorferi (Bb), is transmitted by an Ixodes
scapularis tick attachment lasting 36-48 hrs4
• The characteristic Erythema Migrans (EM) 
Lesion (Bulls Eye or Target Rash) is present in 
70% of infected individuals5
• Other symptoms can manifest days to months 
after a tick bite5
• Symptomology is extremely variable per case 
and ranges from fever and headache to 
neurological and cardiac manifestations5
Fig. 2: Deer Tick (PA’s vector for Lyme) relative size2Fig. 1: Typical EM Lesion1
• Other conditions with nonspecific symptoms can 
mimic Lyme Disease and result in LD 
overdiagnosis. To ensure appropriate treatment, 
a firm diagnosis is needed.5
• Lyme disease can be effectively diagnosed in a 
case approached in a standardized, 
comprehensive clinical approach. The CDC and 
Infectious Diseases Society of America (IDSA) 
provide evidence based guidelines to help 
practitioners cut through the variability of this 
disease. However, these guidelines are not 
applied uniformly in Pennsylvania at this time.3
• PA has the highest number of reported LD cases 
per state; reports of Lyme increased by 110% 
from 2000-20156
• It’s estimated that Lyme Disease costs PA over 
$74 million in lost productivity annually5 
• Keeping these issues in mind, it’s important 
to consider the opportunity for and potential 
benefits of intervention and standardization 









As the retrospective study is still in progress, statistical results 
are not yet available. However, conclusions can still be explored 
from preliminary chart review and background research.
At this time, the most pertinent opportunities for 
standardization and improved care include:
1 Collection of Patient History and Assessment of Risk
• Currently Lyme patient intake and consultation notes are 
at unstandardized practitioner discretion
• Studies show factors like recreational activities and 
symptom duration/evolution may be key considerations 
for a LD diagnosis, yet are not consistently recorded5 7
• An incomplete and nonstandardized patient history may 
result in imprecision with diagnosis and treatment plans.  
2 Serological Testing
• The CDC recommended 2 tier testing algorithm for LD is 
designed to optimize sensitivity and specificity4
• It’s composed of a nonspecific Enzyme-Linked 
Immunosorbent Assay confirmed by a specialized 
Western Blot4
• Studies reveal this system to be ~98.5% and ~90% 
sensitive in late and early stage LD respectively8
• Potential errors in application of this system include:
-performing the 2nd tier of the test and not the 1st, 
(doubling the likelihood of a false positive)
-incorrect timeframe of testing
-performing testing when not clinically indicated8
• The FDA predicts the direct medical cost of 
inaccurate testing to be $1,226 a case (accounting for 
visits, treatments, and testing)9
3 Treatment and Administration of Antibiotics
• Despite established professional society guidelines, 
treatment may be variable. Potential error includes:
-prolonged antibiotic treatment 
-antibiotics without shown efficacy against Bb.
-unstudied alternative treatments4
Patients that receive unneeded antibiotic treatment:
- face unnecessary health risks associated 
with the drug, from minor adverse events (ie
diarrhea) to major ones (ie septic shock)10
Patients that receive delayed antibiotic treatment:
- are at greater risk for disease complications4
- late-stage LD direct healthcare costs are ~$916 
more compared to early-stage LD costs (average
annual LD medical costs being $2,968)11 12
Considering the increasing presence of Lyme Disease in 
the LVHN region, as well as the financial and health risks 
associated with mistreatment/misdiagnosis of this disease, 
there is an enormous opportunity for quality improvement. 
• A retrospective chart review will allow better insight on 
the state of the current system 
• Potential future interventions include development of 
targeted LD training programs for practitioners, EPIC 
prompts during a consult, and enrollment 
questionnaires.
METHODS
A. The opportunity 
for quality of care 
improvements will be 
assessed via 




B. A retrospective 
chart review of patients 
referred to ID department for 
LD from 2015-2016 will be 
carried out with RedCap and 
Excel software, then analyzed 
with 
descriptive statistics. 




Number reported Lyme cases in the Lehigh Valley and 
surrounding counties in 2015, 62.3% increase since 20146
CDC’s prediction that actual cases of Lyme are 10x that 
reported, suggesting there could be as many as 12,480 
annual cases in the LV5
Percent of referrals to LVHN’s Department of Infectious 
Diseases in 2016 that were for Lyme Disease.13
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